Prodly Speeds Adoption of Low Code Big Business Apps for 100 Enterprises
Prodly, which provides reference data management (RDM) solutions for Salesforce users and system integration partners, announced today that in less than two years, it has powered more than 100 big brand customers—including Informatica, Nutanix, Johnson & Johnson, Finastra, Splunk, Tableau, and Verizon—to simplify and automate the arduous process of implementing and maintaining Salesforce applications. The company calls this new category “AppOps,” which enables building, testing, release management and analysis of reference data that is scalable, reliable and repeatable. Prodly raised $3.5 million from Shasta Ventures, with participation from Norwest, to fuel product development and accelerate adoption of its platform.
“We are helping to lower the bar on what it takes to deploy and maintain low-code applications on the Salesforce platform,” said Max Rudman, Prodly’s co-founder and CEO. “By speeding up and simplifying the implementation and maintenance of these enterprise applications, customers can be more agile, respond to business changes faster, and see quicker ROI. That’s a game-changer.”
Empowering Business Users to Drive Digital Transformation
Salesforce has actively acquired and developed a suite of low-code enterprise business applications that enable Salesforce customers to bring about digital transformation more quickly. More than 200,000 Salesforce customers around the world are embracing this low-code application model, but implementing and maintaining these apps remains a challenge. Before Prodly, there were no tools to manage low-code, declarative, reference data-driven applications such as Salesforce CPQ, Salesforce Billing, Salesforce Field Service Lightning, and Salesforce B2B Commerce, as well as applications developed by Salesforce ISV partners. Updating application reference data is a high-frequency, but time-consuming and low-value operation that can take days when done manually. Prodly automates this process, reducing update time from days to minutes, removing the burden on IT, and empowering non-technical users throughout an organization to drive digital transformation.
Prodly’s product roadmap addresses all phases of the reference data management lifecycle. The company plans to expand to other cloud app platforms like SAP, ServiceNow, and Workday, as well.
Repeat Entrepreneur Knows Customer Pain Points First Hand
Prodly co-Founder and CEO Max Rudman was formerly the Founder of SteelBrick, which was acquired by Salesforce for $360 million in 2015. He founded SteelBrick to make CPQ more accessible to Salesforce customers and went on to run the CPQ product at Salesforce. The idea for Prodly emerged out of a pain point experienced by the SteelBrick professional services team in deploying configurations from test environments to production during CPQ implementation projects. There were no tools for automating the deployment of reference data between environments, which led to configuration errors and missed deadlines. It also led to employee retention problems because the work was so time-consuming, boring, and repetitive. With Prodly, Rudman and co-Founder—Daniel Rudman (CTO), an experienced Salesforce architect and developer—set out to build a platform for data reference management. With decades of Salesforce experience and start up success, the team possesses a unique combination of domain expertise and product capability.
“The market that Prodly is going after is massive. Every app deployment needs a product like this - one that helps them to easily manage relational configuration data,” said Nitin Chopra, partner at Shasta. “The Prodly founders have felt the pain of implementing and managing low-code applications and have executed to build an amazing product for that. With Salesforce valued at $12-13 billion, and on its way to $20-$40 billion in five years, Prodly has a really bright future.”
About Prodly
Prodly, a Salesforce ISV partner, solves the time-consuming process that Salesforce administrators, architects, and consultants face: managing the reference data that drives Salesforce applications like CPQ, Billing and Field Service Lightning (FSL). Prodly’s flagship product for reference data management is designed by Salesforce experts for Salesforce administrators and system integration (SI) partners to enable four-click deployment of complex reference data between Salesforce orgs. Prodly is an ideal solution for an agile development process to help Salesforce end users and SI implementation partners drive more ROI from Salesforce applications and eliminate hours of tedious work, increase productivity, and deliver projects on time. For more information visit www.prodly.co.
About Shasta Ventures
Shasta Ventures puts entrepreneurs first. A leading early-stage venture capital firm, Shasta partners with bold creative entrepreneurs who are passionate about building great products that deliver amazing experiences. Founded in 2004, Shasta Ventures has over $1B under management and specializes in consumer, enterprise and emerging platform start-ups. Our portfolio features Anaplan, Apptio, Dollar Shave Club, Glint, Mint, Nest, Zuora and many promising private companies including HighSpot, LeanData, Nextdoor, Smule and Turo. Find out more at www.shastaventures.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190802005054/en/
Contact information
Tori Bealer
+1 (650) 761-6922
tbealer@prodly.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom